RaymondsIndex

Thoma Bravo has been involved in many significant projects, focusing on the acquisition, growth, and enhancement of software and technology companies. Below are comparisons of two notable projects from their portfolio:  1. Acquisition of Ellucian    - Overview: Ellucian is a leading provider of software and services to higher education institutions. Thoma Bravo, along with Blackstone, acquired Ellucian in 2021. The company offers cloud-based software solutions that manage various aspects of educational institutions, from student information to human resources.       - Strategy:      [Buy-and-Build] Thoma Bravo’s approach to Ellucian involved leveraging their expertise in software and cloud technology to accelerate Ellucian's transition to the cloud. This included scaling the company’s cloud offerings and expanding its customer base in the higher education sector.     ...

CDD Summary Overview 2015년 설립하여 사이버보안 분야에 인공지능접목을 시작한 벤처기업 누적매출 약 9년간 약 12억원 투자유치금액 29억원(모두 개인투자) 정부과제 수행 약 6억원  기술력 인정사례 보유: 조달청 혁신기술제품, 가트너리서치 23년 연례보고서에 우수기술로 소개 시장 소구점: OT네트워크 보안에 강점보유한 사이버보안 솔루션 Market diligence reviewing market size assumption 사이버보안시장 규모는 글로벌 200조원, 국내 약 4조원 동사의 기술이 접근하는 시장과는 괴리감 있음  동사는 사이버 보안 체계 전반을 대응하는 솔루션이 아님 -> 기존 보안체계의 WAF 후단에서 미러링되는 데이터를 받아 이상행위를 탐지하는 솔루션  기존 보안솔루션을 대체할 수 없으며, 신규 구축 네트워크에서도 동일하게 WAF 후단에서 작업 동사 기술의 시장은 알려지지 않은 위협을 찾아낸 실적을 기반으로 확장하는 시장을 규정해야 함 → 의미없음 동사가 보는 시장은 unknown threat에 대비해야 하는 고객사에 용역하는 매출 긍정적 시각1: 동사의 유일한 기술성과를 특화하여 제품의 타겟을 좁히고 전문성을 확보한다면 20명 이하 소규모 기업으로 유지 가능 긍정적 시각2: 동사 기술이 탑재된 S/W 또는 어플라이언스 제품의 정체성은 좁혀서 전문화하고 대상 네트워크는 다양화 가능한 초저가부터 최고가까지 다양한 제품 개발 한다면 NAC시장과 같이 안정적 수익 가능성 있음 competitor analysis 동사 제품의 시장은 타겟시장이라고 할 수 없는 시장 제품 비교에 언급하는 경쟁사는 경쟁 영역이 다름 → 고객이 동사 기술에 감동해도 경쟁제품을 대체할 수 있는 제품이 아님 고객이 이를 알면 당황? 동사의 경쟁사는 ‘알려지지 않은 위협’ 탐지 솔루션을 개발하는 제품 또는 기업 ??  BUT 사이버보안 시장의 주류에 속하는 기업들은 기존 제품의 부족한 부분을 보완 또는 진화하는 아이템으로...

CASE 7 Bristol-Myers Squibb and Celgene Merger Overview (2019) 1. Announcement and Motivation:    - The merger between Bristol-Myers Squibb (BMS) and Celgene was announced in January 2019.    - The deal was valued at approximately $74 billion, making it one of the largest mergers in the pharmaceutical industry. 2. Companies Involved:    - Bristol-Myers Squibb (BMS): A global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines for serious diseases.    - Celgene: A biopharmaceutical company known for its expertise in hematology and oncology, particularly in the development of cancer therapies. 3. Purpose and Strategic Rationale:    - The merger aimed to create a leading biopharmaceutical company with a strong presence in oncology, immunology, and cardiovascular disease.    - BMS sought to enhance its pipeline and portfolio of innovative drugs, partic...

CASE 6 Alphabet Inc.'s acquisition of Nest Labs in 2014 1. Announcement and Purchase:    - Date: The acquisition was announced on January 13, 2014.    - Purchase Price: Alphabet Inc. acquired Nest Labs for $3.2 billion in cash. 2. Strategic Rationale:    - Smart Home Technology: Nest Labs was known for its innovative smart home technologies, including the Nest Learning Thermostat and Nest Protect smoke and carbon monoxide detector.    - Entry into IoT: The acquisition aligned with Alphabet's (then Google's) strategic move into the Internet of Things (IoT) and connected home devices.    - Focus on Energy Efficiency: Nest's products, especially the Learning Thermostat, aimed to improve energy efficiency by learning user preferences and optimizing heating and cooling systems. 3. Operational Integration:    - Preservation of Independence: Google allowed Nest Labs to operate as an independent subsidiar...

CASE 5 Cisco's acquisition of Meraki in 2012 Acquisition Overview: - Announcement and Purchase:  Cisco announced its acquisition of Meraki on November 18, 2012. The acquisition was valued at approximately $1.2 billion in cash and marked Cisco's strategic move into cloud-based networking solutions. Strategic Rationale: - Cloud Networking Expertise:  Cisco's acquisition of Meraki was driven by a strategic vision to strengthen its position in cloud-managed networking. Meraki was known for its cloud-based networking solutions that offered simplified management and scalability, making it an attractive addition to Cisco's portfolio. - Mid-Market and SMB Focus:  Meraki's focus on serving mid-market and small to medium-sized businesses (SMBs) aligned with Cisco's goal to expand its offerings to a broader customer base. Operational Integration: - Preservation of Independence:  Cisco allowed Meraki to operate as an independent business unit, preserving its brand, culture,...

Bolt-on strategy Key characters  Here are key characteristics and considerations associated with a bolt-on strategy Strategic Fit:  The acquired business or asset should have a strategic fit with the acquiring company's operations. This means that there should be complementary elements that enhance the overall capabilities, product offerings, or market position of the acquiring company. Easy Integration:  Bolt-on acquisitions are designed to be easily integrated into the existing business structure. This can involve aligning processes, technologies, and personnel to ensure a smooth transition and minimize disruptions. Synergies:  The goal of a bolt-on strategy is often to achieve synergies that benefit both the acquiring and acquired entities. This might involve cost synergies, revenue synergies, or operational efficiencies that result from the combination of resources. Maintaining Autonomy:  In many cases, the acquiring company allows the acquired business to m...

CASE 4 Johnson & Johnson's acquisition of Synthes in 2012   was a significant move in the healthcare and medical technology industry. Here's an explanation of the acquisition: Background Announcement and Agreement Johnson & Johnson (J&J) announced its intention to acquire Synthes, a Swiss medical device company specializing in orthopedic products, in April 2011. The acquisition was valued at approximately $21.3 billion, making it one of the largest in J&J's history. Strategic Rationale Orthopedic Portfolio Enhancement The primary strategic rationale behind the acquisition was to strengthen Johnson & Johnson's presence in the orthopedic market. Synthes was a leading player in the development and manufacturing of orthopedic devices, including implants, instruments, and biomaterials. Market Leadership Synthes had a strong position in trauma and spine products, which complemented J&J's existing orthopedic business. The acquisition aimed to enhanc...